T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer.
Employees: 51-200
Total raised: $110M
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| 26.04.2022 | Life Scien... | lspvc.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.08.2021 | Series B | $110M | - |
Mentions in press and media 4
| Date | Title | Description |
| 10.08.2021 | Digital health news, funding roundup in the prior week; August 9 | PepGen raised $112.5M; Lucid Lane landed $16M; Kensho Health secured $3.5M; DynamiCare Health picks T-knife Therapeutics: T-knife Therapeutics is a Berlin-based, pre-clinical-stage biopharmaceutical company developing tumor-specific T cell ... |
| 03.08.2021 | Someone’s going to hurt from the streaming wars. Blackstone’s plan? Bet on said wars. | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Despite a boom in streaming services during the pandemic, most still agree that the battle betwee... |
| 02.08.2021 | T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies | SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful comp... |
| 02.08.2021 | T-knife Therapeutics Closes $110M Series B Financing | T-knife Therapeutics, Inc., a Berlin, Germany-based T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, completed a $110m Series B financing. The round was led by Fidelity Management & Rese... |